Gerard M P Giblin

This inventor holds 7 USPTO granted patents, plus 1 CIPO patent and 3 EPO patents. Top assignee: Convergence Pharmaceuticals Limited. Active years: 2016-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Gerard M P Giblin. Retrieved from https://idiyas.com/inventor/gerard-m-p-giblin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7

% Patents Active = 14.3

CIPO Patents = 1

EPO Patents = 3 (Patent Applications = 3)

Average Co-Inventor Count = 4.1

ph-index = 3

Forward Citations = 15(Granted Patents)

Location History:

Cambridgeshire, GB (2016)
Cambridge, GB (2016 - 2018)
Cambridge, MA (US) (2019)

Company Filing History:

7 out of 24

Convergence Pharmaceuticals Limited

patents

Years Active: 2016-2019

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10485801 - Pyrimidinyl-diazospiro compounds (2019-11-26),

2. 10010551 - Pyrimidinyl-diazospiro compounds (2018-07-03),

3. 9737536 - Pyrimidinyl-diazospiro compounds (2017-08-22),

4. 9376445 - Pyrimidinyl-diazospiro compounds (2016-06-28),

5. 9376436 - 2-(pyridin-2yl)-1, 7-diaza-spiro [4.4] nonane-6-one compound as voltage-gated sodium channels modulators (2016-06-28),

6. 9309254 - Pyrimidinyl-diazospiro compounds (2016-04-12),

7. 9303032 - 2-(pyridin-2YL)-1, 7-diaza-spiro [4.4] nonane-6-one compound as voltage-gated sodium channels modulator (2016-04-05),

Title: The Innovations of Gerard M P Giblin

Introduction

Gerard M P Giblin is a notable inventor based in Cambridge, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target voltage-gated sodium channels. With a total of seven patents to his name, Giblin's work has the potential to impact the treatment of various diseases.

Latest Patents

Among his latest patents are the Pyrimidinyl-diazospiro compounds. This invention relates to spiro derivatives and their use in treating diseases and conditions mediated by the modulation of voltage-gated sodium channels. The patents also cover compositions containing these derivatives and the processes for their preparation. These innovations highlight Giblin's commitment to advancing medical science through his research.

Career Highlights

Giblin is currently associated with Convergence Pharmaceuticals Limited, where he continues to push the boundaries of pharmaceutical research. His work has garnered attention for its potential applications in treating complex medical conditions.

Collaborations

Throughout his career, Giblin has collaborated with esteemed colleagues such as Steven J Stanway and David MacPherson. These partnerships have likely contributed to the success and development of his innovative ideas.

Conclusion

Gerard M P Giblin's contributions to the field of pharmaceuticals through his patents and collaborations demonstrate his dedication to innovation. His work continues to pave the way for advancements in medical treatments.

Profile summary based on public USPTO records.